Article Versions Notes

Tkachuk AP, Bykonia EN, Popova LI, Kleymenov DA, Semashko MA, Chulanov VP, Fitilev SB, Maksimov SL, Smolyarchuk EA, Manuylov VA, et al. Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study. Vaccines. 2020; 8(4):652. https://doi.org/10.3390/vaccines8040652

Tkachuk, Artem P., Evgeniia N. Bykonia, Liubov I. Popova, Denis A. Kleymenov, Maria A. Semashko, Vladimir P. Chulanov, Sergey B. Fitilev, Semyon L. Maksimov, Elena A. Smolyarchuk, Victor A. Manuylov, and et al. 2020. "Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study" Vaccines 8, no. 4: 652. https://doi.org/10.3390/vaccines8040652

Tkachuk, A. P., Bykonia, E. N., Popova, L. I., Kleymenov, D. A., Semashko, M. A., Chulanov, V. P., Fitilev, S. B., Maksimov, S. L., Smolyarchuk, E. A., Manuylov, V. A., Vasina, D. V., Gushchin, V. A., & Gintsburg, A. L. (2020). Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study. Vaccines, 8(4), 652. https://doi.org/10.3390/vaccines8040652